6533b82efe1ef96bd1293e93

RESEARCH PRODUCT

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra: immunogenicity and safety profile

Volker SchusterHanna CzajkaFred ZeppPaul WillemsMartine DouhaSusanna Esposito

subject

Varicella vaccineImmunization Secondarymedicine.vaccineAntibodies ViralRubellaMeaslesChickenpox VaccinemedicineHumansVaccines CombinedChildClinical Trials as TopicReactogenicityMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantvirus diseasesmedicine.diseaseVirologyVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular MedicinebusinessMeasles-Mumps-Rubella Vaccine

description

Abstract Priorix-Tetra ™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR ( Priorix ™) and varicella ( Varilrix ™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

yearjournalcountryeditionlanguage
2009-11-01
10.1016/j.vaccine.2009.07.076http://hdl.handle.net/11391/1418058